Introduction Chronic pain affects approximatively 30–50% of the population globally.
Pathologies such as migraine, diabetic neuropathy, nerve injury and treatment with …

The neuropeptides calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-
activating polypeptide (PACAP) have emerged as mediators of migraine pathogenesis. Both …

Efficacy of monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (calcitonin receptor-like receptor/receptor activity modifying protein-1, CLR/RAMP1) …

Migraine is the second leading cause for disability worldwide and the most common
neurological disorder. It is also three times more common in women; reasons for this sex …

Introduction: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a
critical player in migraine pathophysiology. Excitement has grown regarding CGRP because …

Migraine is a common condition with disabling attacks that burdens people in the prime of
their working lives. Despite years of research into migraine pathophysiology and …

Migraine afflicts more than 10% of the general population. Although its mechanism is poorly
understood, recent preclinical and clinical evidence has identified calcitonin gene related …

Background Migraine is a common debilitating condition whose main attributes are severe
recurrent headaches with accompanying sensitivity to light and sound, nausea and vomiting …

Objective Cortical spreading depression (SD) is an intense depolarization underlying
migraine aura. Despite the weight of evidence linking SD to the pain phase of migraine …

The CGRP system has emerged as a key pharmacological target for the treatment of
migraine. However, some individuals who suffer from migraine have low or no response to …